doi	section	n_itc	study_number	questions	answer	first	second	third	car_t_cells
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	treatment_name_ipd	teprotumumab	Selective immunosuppressants	NA	NA	FALSE
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	treatment_name_nonipd	intravenous methylprednisolone	Glucocorticoids	NA	NA	FALSE
10.1002/edm2.259	methodology	1	NA	treatment_name_ipd	semaglutide 0.5  +  1 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1002/edm2.259	methodology	1	NA	treatment_name_nonipd	dulaglutide 1.5 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1007/bf03261873	methodology	1	NA	treatment_name_ipd	guanfacine extended-release low dose	Imidazoline receptor agonists	NA	NA	FALSE
10.1007/bf03261873	methodology	1	NA	treatment_name_nonipd	atomoxetine	Centrally acting sympathomimetics	NA	NA	FALSE
10.1007/bf03261873	methodology	2	NA	treatment_name_ipd	guanfacine extended-release mid dose	Imidazoline receptor agonists	NA	NA	FALSE
10.1007/bf03261873	methodology	2	NA	treatment_name_nonipd	atomoxetine	Centrally acting sympathomimetics	NA	NA	FALSE
10.1007/bf03261873	methodology	3	NA	treatment_name_ipd	guanfacine extended-release high dose	Imidazoline receptor agonists	NA	NA	FALSE
10.1007/bf03261873	methodology	3	NA	treatment_name_nonipd	atomoxetine	Centrally acting sympathomimetics	NA	NA	FALSE
10.1007/s00432-021-03602-w	methodology	1	NA	treatment_name_ipd	regorafenib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s00432-021-03602-w	methodology	1	NA	treatment_name_nonipd	cabozantinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s11523-021-00803-8	methodology	1	NA	treatment_name_ipd	lenvatinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s11523-021-00803-8	methodology	1	NA	treatment_name_nonipd	atezolizumab + bevacizumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1007/s12325-014-0167-z	methodology	1	NA	treatment_name_ipd	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	1	NA	treatment_name_nonipd	dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	2	NA	treatment_name_ipd	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	2	NA	treatment_name_nonipd	teriflunomide 7 mg	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	3	NA	treatment_name_ipd	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-014-0167-z	methodology	3	NA	treatment_name_nonipd	teriflunomide 14 mg	Selective immunosuppressants	NA	NA	FALSE
10.1007/s12325-017-0564-1	methodology	1	NA	treatment_name_ipd	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1007/s12325-017-0564-1	methodology	1	NA	treatment_name_nonipd	obinutuzumab + chlorambucil	Monoclonal antibodies	Nitrogen mustard analogues	NA	FALSE
10.1007/s12325-018-0734-9	methodology	1	NA	treatment_name_ipd	dabrafenib + trametinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.1007/s12325-018-0734-9	methodology	1	NA	treatment_name_nonipd	nivolumab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-00991-w	methodology	1	NA	treatment_name_ipd	inotuzumab ozogamicin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-00991-w	methodology	1	NA	treatment_name_nonipd	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-00991-w	methodology	2	NA	treatment_name_ipd	inotuzumab ozogamicin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-00991-w	methodology	2	NA	treatment_name_nonipd	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-01156-5	methodology	1	NA	treatment_name_ipd	apalutamide	Anti-androgens	NA	NA	FALSE
10.1007/s12325-019-01156-5	methodology	1	NA	treatment_name_nonipd	enzalutamide	Anti-androgens	NA	NA	FALSE
10.1007/s12325-019-01157-4	methodology	1	NA	treatment_name_ipd	apalutamide	Anti-androgens	NA	NA	FALSE
10.1007/s12325-019-01157-4	methodology	1	NA	treatment_name_nonipd	enzalutamide	Anti-androgens	NA	NA	FALSE
10.1007/s12325-019-01173-4	methodology	1	NA	treatment_name_ipd	ratiofrequency catheter ablation with ablation index	procedure	NA	NA	FALSE
10.1007/s12325-019-01173-4	methodology	1	NA	treatment_name_nonipd	ratiofrequency catheter ablation with cryoballoon	procedure	NA	NA	FALSE
10.1007/s12325-019-0873-7	methodology	1	NA	treatment_name_ipd	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-0873-7	methodology	1	NA	treatment_name_nonipd	inotuzumab ozogamicin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-0873-7	methodology	2	NA	treatment_name_ipd	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-019-0873-7	methodology	2	NA	treatment_name_nonipd	inotuzumab ozogamicin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-020-01298-x	methodology	1	NA	treatment_name_ipd	intravitreally administered aflibercept (ivt-afl) with 2 weeks adjustment	Antineovascularisation agents	NA	NA	FALSE
10.1007/s12325-020-01298-x	methodology	1	NA	treatment_name_nonipd	intravitreally administered aflibercept (ivt-afl) : one injection every 8 weeks in the first year followed by prorenata regimen in the second year	NA	NA	NA	NA
10.1007/s12325-020-01378-y	methodology	1	NA	treatment_name_ipd	cabozantinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s12325-020-01378-y	methodology	1	NA	treatment_name_nonipd	regorafenib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	1	NA	treatment_name_ipd	recombinant fviiifc	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	1	NA	treatment_name_nonipd	damoctocog alfa pegol (pooled prophylaxis)	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	2	NA	treatment_name_ipd	recombinant fviiifc	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	2	NA	treatment_name_nonipd	damoctocog alfa pegol twice weekly	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	3	NA	treatment_name_ipd	recombinant fviiifc	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	3	NA	treatment_name_nonipd	damoctocog alfa pegol q5d	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	4	NA	treatment_name_ipd	recombinant fviiifc	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-020-01599-1	methodology	4	NA	treatment_name_nonipd	damoctocog alfa pegol q7d	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01700-2	methodology	1	NA	treatment_name_ipd	cabozantinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s12325-021-01700-2	methodology	1	NA	treatment_name_nonipd	ramucirumab	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-021-01756-0	methodology	1	NA	treatment_name_ipd	lisocabtagene maraleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1007/s12325-021-01756-0	methodology	1	NA	treatment_name_nonipd	salvage chemotherapy	ANTINEOPLASTIC AGENTS	NA	NA	FALSE
10.1007/s12325-021-01846-z	methodology	1	NA	treatment_name_ipd	thermocool smarttouch /thermocool smarttouch sf catheter with ai (stai)	NA	NA	NA	NA
10.1007/s12325-021-01846-z	methodology	1	NA	treatment_name_nonipd	second-generation cryoballoon (cb)	procedure	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	1	NA	treatment_name_ipd	rviii-singlechain	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	1	NA	treatment_name_nonipd	rahf-pfm	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	2	NA	treatment_name_ipd	rviii-singlechain	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	2	NA	treatment_name_nonipd	rahf-pfm	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	3	NA	treatment_name_ipd	rviii-singlechain	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01853-0	methodology	3	NA	treatment_name_nonipd	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.1007/s12325-021-01884-7	methodology	1	NA	treatment_name_ipd	belantamab mafodotin	Monoclonal antibodies	NA	NA	FALSE
10.1007/s12325-021-01884-7	methodology	1	NA	treatment_name_nonipd	selinexor + dexamethasone	Other antineoplastic agents	Glucocorticoids	NA	FALSE
10.1007/s12325-021-01885-6	methodology	1	NA	treatment_name_ipd	apalutamide + adt	Anti-androgens	Anti-androgens	NA	FALSE
10.1007/s12325-021-01885-6	methodology	1	NA	treatment_name_nonipd	darolutamide + adt	Anti-androgens	Anti-androgens	NA	FALSE
10.1007/s12325-022-02054-z	methodology	1	NA	treatment_name_ipd	tazemetostat	Other antineoplastic agents	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	1	NA	treatment_name_nonipd	idelalisib	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	2	NA	treatment_name_ipd	tazemetostat	Other antineoplastic agents	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	2	NA	treatment_name_nonipd	duvelisib	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	3	NA	treatment_name_ipd	tazemetostat	Other antineoplastic agents	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	3	NA	treatment_name_nonipd	copanlisib	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	4	NA	treatment_name_ipd	tazemetostat	Other antineoplastic agents	NA	NA	FALSE
10.1007/s12325-022-02054-z	methodology	4	NA	treatment_name_nonipd	umbralisib	Other protein kinase inhibitors	NA	NA	FALSE
10.1007/s12325-022-02099-0	methodology	1	NA	treatment_name_ipd	transarterial radioembolization	NA	NA	NA	NA
10.1007/s12325-022-02099-0	methodology	1	NA	treatment_name_nonipd	atezolizumab + bevacizumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1007/s13555-021-00646-1	methodology	1	NA	treatment_name_ipd	crisaborole ointment 2	Agents for dermatitis, excluding corticosteroids	NA	NA	FALSE
10.1007/s13555-021-00646-1	methodology	1	NA	treatment_name_nonipd	pimecrolimus 1	NA	NA	NA	NA
10.1007/s13555-021-00646-1	methodology	2	NA	treatment_name_ipd	crisaborole	Agents for dermatitis, excluding corticosteroids	NA	NA	FALSE
10.1007/s13555-021-00646-1	methodology	2	NA	treatment_name_nonipd	tacrolimus 0.03	NA	NA	NA	NA
10.1007/s40258-016-0271-0	methodology	1	NA	treatment_name_ipd	panobinostat + bortezomib + dexamethasone	Histone deacetylase (HDAC) inhibitors	Proteasome inhibitors	Glucocorticoids	FALSE
10.1007/s40258-016-0271-0	methodology	1	NA	treatment_name_nonipd	lenalidomide + dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.1007/s40263-013-0102-x	methodology	1	NA	treatment_name_ipd	guanfacine extended release	Imidazoline receptor agonists	NA	NA	FALSE
10.1007/s40263-013-0102-x	methodology	1	NA	treatment_name_nonipd	atomoxetine	Centrally acting sympathomimetics	NA	NA	FALSE
10.1007/s40263-019-00672-w	methodology	1	NA	treatment_name_ipd	brexanolone	PSYCHOANALEPTICS	NA	NA	FALSE
10.1007/s40263-019-00672-w	methodology	1	NA	treatment_name_nonipd	placebo	placebo	NA	NA	FALSE
10.1007/s40263-021-00805-0	methodology	1	NA	treatment_name_ipd	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.1007/s40263-021-00805-0	methodology	1	NA	treatment_name_nonipd	dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.1007/s40273-021-01015-8	methodology	1	NA	treatment_name_ipd	lorlatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1007/s40273-021-01015-8	methodology	1	NA	treatment_name_nonipd	pemetrexed or docetaxel	Folic acid analogues	Taxanes	NA	FALSE
10.1007/s40273-021-01015-8	methodology	2	NA	treatment_name_ipd	lorlatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1007/s40273-021-01015-8	methodology	2	NA	treatment_name_nonipd	systemic therapy	supportive or standard of care	NA	NA	FALSE
10.1007/s40744-017-0070-6	methodology	1	NA	treatment_name_ipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-017-0070-6	methodology	1	NA	treatment_name_nonipd	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-017-0070-6	methodology	2	NA	treatment_name_ipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-017-0070-6	methodology	2	NA	treatment_name_nonipd	secukinumab 300 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	1	NA	treatment_name_ipd	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	1	NA	treatment_name_nonipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	2	NA	treatment_name_ipd	secukinumab 300 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	2	NA	treatment_name_nonipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	3	NA	treatment_name_ipd	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	3	NA	treatment_name_nonipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	4	NA	treatment_name_ipd	secukinumab 300 mg	Interleukin inhibitors	NA	NA	FALSE
10.1007/s40744-018-0106-6	methodology	4	NA	treatment_name_nonipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1007/s40744-020-00257-w	methodology	1	NA	treatment_name_ipd	upadacitinib monotherapy	Selective immunosuppressants	NA	NA	FALSE
10.1007/s40744-020-00257-w	methodology	1	NA	treatment_name_nonipd	tofacitinib + methotrexate	Selective immunosuppressants	Folic acid analogues	NA	FALSE
10.1007/s40744-020-00257-w	methodology	2	NA	treatment_name_ipd	upadacitinib + methotrexate	Selective immunosuppressants	Folic acid analogues	NA	FALSE
10.1007/s40744-020-00257-w	methodology	2	NA	treatment_name_nonipd	tofacitinib + methotrexate	Selective immunosuppressants	Folic acid analogues	NA	FALSE
10.1016/j.bbmt.2020.06.008	methodology	1	NA	treatment_name_ipd	axicabtagene ciloleucel	Other antineoplastic agents	NA	NA	TRUE
10.1016/j.bbmt.2020.06.008	methodology	1	NA	treatment_name_nonipd	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.1016/j.clgc.2020.07.006	methodology	1	NA	treatment_name_ipd	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.1016/j.clgc.2020.07.006	methodology	1	NA	treatment_name_nonipd	carboplatin + gemcitabine	Platinum compounds	Pyrimidine analogues	NA	FALSE
10.1016/j.clinthera.2015.09.013	methodology	1	NA	treatment_name_ipd	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2015.09.013	methodology	1	NA	treatment_name_nonipd	axitinib	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2015.12.017	methodology	1	NA	treatment_name_ipd	daclatasvir + sofosbuvir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.1016/j.clinthera.2015.12.017	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ribavirin	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.1016/j.clinthera.2017.08.010	methodology	1	NA	treatment_name_ipd	pomalidomide + dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.1016/j.clinthera.2017.08.010	methodology	1	NA	treatment_name_nonipd	daratumumab	Monoclonal antibodies	NA	NA	FALSE
10.1016/j.clinthera.2017.08.010	methodology	2	NA	treatment_name_ipd	pomalidomide + dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.1016/j.clinthera.2017.08.010	methodology	2	NA	treatment_name_nonipd	carfilzomib	Proteasome inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	1	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	1	NA	treatment_name_nonipd	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	2	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	2	NA	treatment_name_nonipd	bortezomib	Proteasome inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	3	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	3	NA	treatment_name_nonipd	lenalidomide	Other immunosuppressants	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	4	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	4	NA	treatment_name_nonipd	temsirolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	5	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	5	NA	treatment_name_nonipd	ibrutinib + rituximab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	6	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	6	NA	treatment_name_nonipd	bendamustine + rituximab	Nitrogen mustard analogues	Monoclonal antibodies	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	7	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1016/j.clinthera.2019.09.012	methodology	7	NA	treatment_name_nonipd	lenalidomide + rituximab	Other immunosuppressants	Monoclonal antibodies	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	treatment_name_ipd	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	treatment_name_nonipd	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	treatment_name_ipd	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	treatment_name_nonipd	best supportive care (bsc)	supportive or standard of care	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	treatment_name_ipd	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	treatment_name_nonipd	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	treatment_name_ipd	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	treatment_name_nonipd	best supportive care	supportive or standard of care	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	treatment_name_ipd	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	treatment_name_nonipd	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	treatment_name_ipd	[177lu]lu-dota-tate	Various therapeutic radiopharmaceuticals	NA	NA	FALSE
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	treatment_name_nonipd	best supportive care	supportive or standard of care	NA	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	1	NA	treatment_name_nonipd	dabrafenib + trametinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	2	NA	treatment_name_ipd	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	2	NA	treatment_name_nonipd	encorafenib + binimetinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	3	NA	treatment_name_ipd	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.1016/j.esmoop.2021.100050	methodology	3	NA	treatment_name_nonipd	vemurafenib + cobimetinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.1016/j.euo.2018.09.009	methodology	1	NA	treatment_name_ipd	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.1016/j.euo.2018.09.009	methodology	1	NA	treatment_name_nonipd	carboplatin + gemcitabine	Platinum compounds	Pyrimidine analogues	NA	FALSE
10.1016/j.euo.2018.09.009	methodology	2	NA	treatment_name_ipd	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.1016/j.euo.2018.09.009	methodology	2	NA	treatment_name_nonipd	gemcitabine	Pyrimidine analogues	NA	NA	FALSE
10.1016/j.jtho.2016.05.029	methodology	1	NA	treatment_name_ipd	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1016/j.jtho.2016.05.029	methodology	1	NA	treatment_name_nonipd	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1016/j.jval.2018.03.015	methodology	1	NA	treatment_name_ipd	magnetic resonance-guided focused ultrasound	procedure	NA	NA	FALSE
10.1016/j.jval.2018.03.015	methodology	1	NA	treatment_name_nonipd	unilateral deep brain stimulation	procedure	NA	NA	FALSE
10.1016/j.jval.2018.03.015	methodology	2	NA	treatment_name_ipd	magnetic resonance-guided focused ultrasound	procedure	NA	NA	FALSE
10.1016/j.jval.2018.03.015	methodology	2	NA	treatment_name_nonipd	unilateral deep brain stimulation (dbs)	procedure	NA	NA	FALSE
10.1016/j.lungcan.2021.03.020	methodology	1	NA	treatment_name_ipd	pembrolizumab + chemotherapy	Monoclonal antibodies	ANTINEOPLASTIC AGENTS	NA	FALSE
10.1016/j.lungcan.2021.03.020	methodology	1	NA	treatment_name_nonipd	atezolizumab + chemotherapy	Monoclonal antibodies	ANTINEOPLASTIC AGENTS	NA	FALSE
10.1016/j.lungcan.2021.03.020	methodology	2	NA	treatment_name_ipd	pembrolizumab + chemotherapy	Monoclonal antibodies	ANTINEOPLASTIC AGENTS	NA	FALSE
10.1016/j.lungcan.2021.03.020	methodology	2	NA	treatment_name_nonipd	atezolizumab + bevacizumab + chemotherapy	Monoclonal antibodies	Monoclonal antibodies	ANTINEOPLASTIC AGENTS	FALSE
10.1016/j.msard.2021.102972	methodology	1	NA	treatment_name_ipd	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.1016/j.msard.2021.102972	methodology	1	NA	treatment_name_nonipd	teriflunomide	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2016.1248380	methodology	1	NA	treatment_name_ipd	dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.1080/03007995.2016.1248380	methodology	1	NA	treatment_name_nonipd	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2018.1510225	methodology	1	NA	treatment_name_ipd	ponatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1510225	methodology	1	NA	treatment_name_nonipd	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	1	NA	treatment_name_ipd	brigatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	1	NA	treatment_name_nonipd	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	2	NA	treatment_name_ipd	brigatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	2	NA	treatment_name_nonipd	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	3	NA	treatment_name_ipd	brigatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	3	NA	treatment_name_nonipd	alectinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	4	NA	treatment_name_ipd	brigatinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1520696	methodology	4	NA	treatment_name_nonipd	alectinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1541443	methodology	1	NA	treatment_name_ipd	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2018.1541443	methodology	1	NA	treatment_name_nonipd	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/03007995.2019.1585779	methodology	1	NA	treatment_name_ipd	cladribine	Purine analogues	NA	NA	FALSE
10.1080/03007995.2019.1585779	methodology	1	NA	treatment_name_nonipd	alemtuzumab	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2019.1605239	methodology	1	NA	treatment_name_ipd	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2019.1605239	methodology	1	NA	treatment_name_nonipd	dasatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2019.1605239	methodology	2	NA	treatment_name_ipd	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2019.1605239	methodology	2	NA	treatment_name_nonipd	nilotinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	1	NA	treatment_name_ipd	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	1	NA	treatment_name_nonipd	ifnÎ²-1b 250 Î¼g once every other day (q2d)	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	2	NA	treatment_name_ipd	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	2	NA	treatment_name_nonipd	ifnÎ²-1a 22 Î¼g once weekly (qw)	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	3	NA	treatment_name_ipd	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	3	NA	treatment_name_nonipd	natalizumab	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	4	NA	treatment_name_ipd	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	4	NA	treatment_name_nonipd	sc ifnÎ²-1a 22 Î¼g three times weekly	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	5	NA	treatment_name_ipd	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	5	NA	treatment_name_nonipd	sc ifnÎ²-1a 44 Î¼g three times weekly	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	6	NA	treatment_name_ipd	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	6	NA	treatment_name_nonipd	ifnÎ²-1b 8 miu once every other day	Interferons	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	7	NA	treatment_name_ipd	siponimod	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2020.1747999	methodology	7	NA	treatment_name_nonipd	im ifnÎ²-1a 60 Î¼g once weekly	Interferons	NA	NA	FALSE
10.1080/03007995.2021.1896489	methodology	1	NA	treatment_name_ipd	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2021.1896489	methodology	1	NA	treatment_name_nonipd	nilotinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2021.1896489	methodology	2	NA	treatment_name_ipd	bosutinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2021.1896489	methodology	2	NA	treatment_name_nonipd	dasatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1080/03007995.2021.1947216	methodology	1	NA	treatment_name_ipd	onasemnogene abeparvovec	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.1080/03007995.2021.1947216	methodology	1	NA	treatment_name_nonipd	nusinersen	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.1080/03007995.2021.1953456	methodology	1	NA	treatment_name_ipd	ciltacabtagene autoleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1080/03007995.2021.1953456	methodology	1	NA	treatment_name_nonipd	idecabtagene vicleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1080/03007995.2021.1971182	methodology	1	NA	treatment_name_ipd	pegcetacoplan	IMMUNOSUPPRESSANTS	NA	NA	FALSE
10.1080/03007995.2021.1971182	methodology	1	NA	treatment_name_nonipd	ravulizumab	Selective immunosuppressants	NA	NA	FALSE
10.1080/03007995.2022.2030112	methodology	1	NA	treatment_name_ipd	amlodipine 5 mg + bisoprolol 5 mg	Dihydropyridine derivatives	Beta blocking agents, selective	NA	FALSE
10.1080/03007995.2022.2030112	methodology	1	NA	treatment_name_nonipd	amlodipine 10mg,	Dihydropyridine derivatives	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	1	NA	treatment_name_ipd	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	1	NA	treatment_name_nonipd	guselkumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	2	NA	treatment_name_ipd	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	2	NA	treatment_name_nonipd	tildrakizumab 100mg	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	3	NA	treatment_name_ipd	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	3	NA	treatment_name_nonipd	tildrakizumab 200mg	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	4	NA	treatment_name_ipd	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	4	NA	treatment_name_nonipd	tildrakizumab 100mg	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	5	NA	treatment_name_ipd	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	5	NA	treatment_name_nonipd	tildrakizumab 200mg	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	6	NA	treatment_name_ipd	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	6	NA	treatment_name_nonipd	risankizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	7	NA	treatment_name_ipd	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/09546634.2020.1747592	methodology	7	NA	treatment_name_nonipd	risankizumab	Interleukin inhibitors	NA	NA	FALSE
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_ipd	vmp (bortezomib/melphalan/prednisone)	NA	Nitrogen mustard analogues	NA	FALSE
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_nonipd	modified vmp schedule	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_ipd	daratumumab–bortezomib–melphalan–prednisone	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_nonipd	lenalidomide–dexamethasone continuous	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_ipd	daratumumab–bortezomib–melphalan–prednisone	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_nonipd	lenalidomide–dexamethasone 18 months (rd18)	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_ipd	daratumumab–bortezomib–melphalan–prednisone	NA	NA	NA	NA
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_nonipd	melphalan–prednisone–thalidomide	NA	NA	NA	NA
10.1080/10428194.2021.1913143	methodology	1	NA	treatment_name_ipd	idecabtagene vicleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1080/10428194.2021.1913143	methodology	1	NA	treatment_name_nonipd	selinexor + dexamethasone	Other antineoplastic agents	Glucocorticoids	NA	FALSE
10.1080/10428194.2021.1913143	methodology	2	NA	treatment_name_ipd	idecabtagene + vicleucel	ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC AGENTS	NA	TRUE
10.1080/10428194.2021.1913143	methodology	2	NA	treatment_name_nonipd	belantamab mafodotin	Monoclonal antibodies	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	1	NA	treatment_name_ipd	acalabrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	1	NA	treatment_name_nonipd	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	2	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	2	NA	treatment_name_nonipd	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	3	NA	treatment_name_ipd	acalabrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	3	NA	treatment_name_nonipd	ibrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	4	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	4	NA	treatment_name_nonipd	ibrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	5	NA	treatment_name_ipd	acalabrutinib + obinutuzumab	Bruton's tyrosine kinase (BTK) inhibitors	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	5	NA	treatment_name_nonipd	venetoclax + obinutuzumab	Other antineoplastic agents	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.1913144	methodology	6	NA	treatment_name_ipd	acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA	FALSE
10.1080/10428194.2021.1913144	methodology	6	NA	treatment_name_nonipd	venetoclax + obinutuzumab	Other antineoplastic agents	Monoclonal antibodies	NA	FALSE
10.1080/10428194.2021.2010069	methodology	1	NA	treatment_name_ipd	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.1080/10428194.2021.2010069	methodology	1	NA	treatment_name_nonipd	lisocabtagene	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_ipd	carfizomib + dexamethasone+daratumumab	Proteasome inhibitors	Glucocorticoids	Monoclonal antibodies	FALSE
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_nonipd	daratumumab + velcade+dexamethasone	Monoclonal antibodies	Proteasome inhibitors	Glucocorticoids	FALSE
10.1080/13696998.2018.1443111	methodology	1	NA	treatment_name_ipd	ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/13696998.2018.1443111	methodology	1	NA	treatment_name_nonipd	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.1080/13696998.2020.1722139	methodology	1	NA	treatment_name_ipd	calcipotriene 0.005/betamethasone dipropionate 0.064% foam	NA	NA	NA	NA
10.1080/13696998.2020.1722139	methodology	1	NA	treatment_name_nonipd	halobetasol 0.01/tazarotene 0.045%	NA	NA	NA	NA
10.1080/14656566.2020.1811850	methodology	1	NA	treatment_name_ipd	patisiran	Other nervous system drugs	NA	NA	FALSE
10.1080/14656566.2020.1811850	methodology	1	NA	treatment_name_nonipd	inotersen	Other nervous system drugs	NA	NA	FALSE
10.1080/14760584.2021.1994858	methodology	1	NA	treatment_name_ipd	15-valent pneumococcal conjugate vaccine	Pneumococcal vaccines	NA	NA	FALSE
10.1080/14760584.2021.1994858	methodology	1	NA	treatment_name_nonipd	20-valent pneumococcal conjugate vaccine	Pneumococcal vaccines	NA	NA	FALSE
10.1080/17474086.2018.1475226	methodology	1	NA	treatment_name_ipd	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.1080/17474086.2018.1475226	methodology	1	NA	treatment_name_nonipd	st + ard of care	NA	supportive or standard of care	NA	FALSE
10.1093/europace/euy160	methodology	1	NA	treatment_name_ipd	rivaroxaban	Direct factor Xa inhibitors	NA	NA	FALSE
10.1093/europace/euy160	methodology	1	NA	treatment_name_nonipd	rivaroxaban	Direct factor Xa inhibitors	NA	NA	FALSE
10.1093/jnci/djab071	methodology	1	NA	treatment_name_ipd	abiraterone acetate	Other hormone antagonists and related agents	NA	NA	FALSE
10.1093/jnci/djab071	methodology	1	NA	treatment_name_nonipd	placebo	placebo	NA	NA	FALSE
10.1097/brs.0000000000002647	methodology	1	NA	treatment_name_ipd	total disc replacement	NA	NA	NA	NA
10.1097/brs.0000000000002647	methodology	1	NA	treatment_name_nonipd	fusion	NA	NA	NA	NA
10.1097/ju.0000000000001767	methodology	1	NA	treatment_name_ipd	darolutamide	Anti-androgens	NA	NA	FALSE
10.1097/ju.0000000000001767	methodology	1	NA	treatment_name_nonipd	apalutamide	Anti-androgens	NA	NA	FALSE
10.1097/ju.0000000000001767	methodology	2	NA	treatment_name_ipd	darolutamide	Anti-androgens	NA	NA	FALSE
10.1097/ju.0000000000001767	methodology	2	NA	treatment_name_nonipd	enzalutamide	Anti-androgens	NA	NA	FALSE
10.1111/bjd.16140	methodology	3	NA	treatment_name_ipd	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	3	NA	treatment_name_nonipd	secukinumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	5	NA	treatment_name_ipd	ixekizumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/bjd.16140	methodology	5	NA	treatment_name_nonipd	secukinumab	Interleukin inhibitors	NA	NA	FALSE
10.1111/cea.13561	methodology	1	NA	treatment_name_ipd	benralizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1111/cea.13561	methodology	1	NA	treatment_name_nonipd	mepolizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1111/cea.13561	methodology	2	NA	treatment_name_ipd	benralizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1111/cea.13561	methodology	2	NA	treatment_name_nonipd	dupilumab	Agents for dermatitis, excluding corticosteroids	NA	NA	FALSE
10.1111/dom.14497	methodology	1	NA	treatment_name_ipd	semaglutide 1.0mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1111/dom.14497	methodology	1	NA	treatment_name_nonipd	dulaglutide 3.0mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1111/dom.14497	methodology	2	NA	treatment_name_ipd	semaglutide 1.0mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1111/dom.14497	methodology	2	NA	treatment_name_nonipd	dulaglutide 4.5mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1111/head.14128	methodology	1	NA	treatment_name_ipd	rimegepant	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	1	NA	treatment_name_nonipd	placebo	placebo	NA	NA	FALSE
10.1111/head.14128	methodology	2	NA	treatment_name_ipd	rimegepant	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	2	NA	treatment_name_nonipd	galcanezumab	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	3	NA	treatment_name_ipd	rimegepant	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	3	NA	treatment_name_nonipd	placebo	placebo	NA	NA	FALSE
10.1111/head.14128	methodology	4	NA	treatment_name_ipd	rimegepant	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/head.14128	methodology	4	NA	treatment_name_nonipd	erenumab	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA	FALSE
10.1111/jdv.15369	methodology	1	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	Other antipsoriatics for topical use	Corticosteroids, potent, other combinations	NA	FALSE
10.1111/jdv.15369	methodology	1	NA	treatment_name_nonipd	apremilast	Selective immunosuppressants	NA	NA	FALSE
10.1111/jdv.15369	methodology	2	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	Other antipsoriatics for topical use	Corticosteroids, potent, other combinations	NA	FALSE
10.1111/jdv.15369	methodology	2	NA	treatment_name_nonipd	methotrexate	Folic acid analogues	NA	NA	FALSE
10.1111/jdv.15369	methodology	3	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	Other antipsoriatics for topical use	Corticosteroids, potent, other combinations	NA	FALSE
10.1111/jdv.15369	methodology	3	NA	treatment_name_nonipd	acitretin	Retinoids for treatment of psoriasis	NA	NA	FALSE
10.1111/jdv.15369	methodology	4	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	Other antipsoriatics for topical use	Corticosteroids, potent, other combinations	NA	FALSE
10.1111/jdv.15369	methodology	4	NA	treatment_name_nonipd	fumaric acid esters	Other antipsoriatics for systemic use	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	1	NA	treatment_name_ipd	baricitinib	Selective immunosuppressants	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	1	NA	treatment_name_nonipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	2	NA	treatment_name_ipd	baricitinib	Selective immunosuppressants	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	2	NA	treatment_name_nonipd	tocilizumab	Interleukin inhibitors	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	3	NA	treatment_name_ipd	baricitinib	Selective immunosuppressants	NA	NA	FALSE
10.1136/rmdopen-2019-001131	methodology	3	NA	treatment_name_nonipd	tofacitinib	Selective immunosuppressants	NA	NA	FALSE
10.1155/2017/6121760	methodology	1	NA	treatment_name_ipd	sonidegib	Hedgehog pathway inhibitors	NA	NA	FALSE
10.1155/2017/6121760	methodology	1	NA	treatment_name_nonipd	vismodegib	Hedgehog pathway inhibitors	NA	NA	FALSE
10.1177/1756286420975916	methodology	1	NA	treatment_name_ipd	peginterferon beta-1a	Interferons	NA	NA	FALSE
10.1177/1756286420975916	methodology	1	NA	treatment_name_nonipd	glatiramer acetate	Other immunostimulants	NA	NA	FALSE
10.1177/17588359211049639	methodology	1	NA	treatment_name_ipd	olaparib + bevacizumab	Poly (ADP-ribose) polymerase (PARP) inhibitors	Monoclonal antibodies	NA	FALSE
10.1177/17588359211049639	methodology	1	NA	treatment_name_nonipd	niraparib	Poly (ADP-ribose) polymerase (PARP) inhibitors	NA	NA	FALSE
10.1177/17588359211049639	methodology	2	NA	treatment_name_ipd	bevacizumab + placebo	Monoclonal antibodies	placebo	NA	FALSE
10.1177/17588359211049639	methodology	2	NA	treatment_name_nonipd	niraparib	Poly (ADP-ribose) polymerase (PARP) inhibitors	NA	NA	FALSE
10.1177/17588359211049639	methodology	3	NA	treatment_name_ipd	olaparib + bevacizumab	Poly (ADP-ribose) polymerase (PARP) inhibitors	Monoclonal antibodies	NA	FALSE
10.1177/17588359211049639	methodology	3	NA	treatment_name_nonipd	placebo	placebo	NA	NA	FALSE
10.1177/17588359211049639	methodology	4	NA	treatment_name_ipd	placebo + bevacizumab	placebo	Monoclonal antibodies	NA	FALSE
10.1177/17588359211049639	methodology	4	NA	treatment_name_nonipd	placebo	placebo	NA	NA	FALSE
10.1183/13993003.01393-2018	methodology	1	NA	treatment_name_ipd	benralizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1183/13993003.01393-2018	methodology	1	NA	treatment_name_nonipd	mepolizumab	Other systemic drugs for obstructive airway diseases	NA	NA	FALSE
10.1185/03007995.2011.576238	methodology	1	NA	treatment_name_ipd	nilotinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1185/03007995.2011.576238	methodology	1	NA	treatment_name_nonipd	dasatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1185/03007995.2014.977992	methodology	1	NA	treatment_name_ipd	nilotinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1185/03007995.2014.977992	methodology	1	NA	treatment_name_nonipd	dasatinib	Bcr-abl tyrosine kinase inhibitors	NA	NA	FALSE
10.1185/03007995.2015.1106934	methodology	1	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	1	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1185/03007995.2015.1106934	methodology	2	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	2	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1185/03007995.2015.1106934	methodology	3	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	3	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1185/03007995.2015.1106934	methodology	4	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	4	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1185/03007995.2015.1106934	methodology	5	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.1185/03007995.2015.1106934	methodology	5	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.1186/2162-3619-2-32	methodology	1	NA	treatment_name_ipd	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	1	NA	treatment_name_nonipd	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	2	NA	treatment_name_ipd	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	2	NA	treatment_name_nonipd	placebo	placebo	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	3	NA	treatment_name_ipd	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1186/2162-3619-2-32	methodology	3	NA	treatment_name_nonipd	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1186/s12885-018-5157-0	methodology	1	NA	treatment_name_ipd	axitinib	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.1186/s12885-018-5157-0	methodology	1	NA	treatment_name_nonipd	cabozantinib	Other protein kinase inhibitors	NA	NA	FALSE
10.1186/s12885-018-5157-0	methodology	2	NA	treatment_name_ipd	axitinib	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.1186/s12885-018-5157-0	methodology	2	NA	treatment_name_nonipd	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.1186/s13045-021-01144-9	methodology	1	NA	treatment_name_ipd	lisocabtagene maraleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1186/s13045-021-01144-9	methodology	1	NA	treatment_name_nonipd	axicabtagene ciloleucel	Other antineoplastic agents	NA	NA	TRUE
10.1186/s40164-022-00268-z	methodology	1	NA	treatment_name_ipd	lisocabtagene maraleucel	ANTINEOPLASTIC AGENTS	NA	NA	TRUE
10.1186/s40164-022-00268-z	methodology	1	NA	treatment_name_nonipd	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.1186/s40734-017-0051-5	methodology	1	NA	treatment_name_ipd	deutetrabenazine	Other nervous system drugs	NA	NA	FALSE
10.1186/s40734-017-0051-5	methodology	1	NA	treatment_name_nonipd	tetrabenazine	Other nervous system drugs	NA	NA	FALSE
10.1210/clinem/dgab905	methodology	1	NA	treatment_name_ipd	semaglutide 2.0 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1210/clinem/dgab905	methodology	1	NA	treatment_name_nonipd	dulaglutide 3.0 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1210/clinem/dgab905	methodology	2	NA	treatment_name_ipd	semaglutide 2.0 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1210/clinem/dgab905	methodology	2	NA	treatment_name_nonipd	dulaglutide 4.5 mg	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA	FALSE
10.1634/theoncologist.2017-0103	methodology	1	NA	treatment_name_ipd	daratumumab	Monoclonal antibodies	NA	NA	FALSE
10.1634/theoncologist.2017-0103	methodology	1	NA	treatment_name_nonipd	pomalidomide + low-dose dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.1634/theoncologist.2017-0103	methodology	2	NA	treatment_name_ipd	daratumumab	Monoclonal antibodies	NA	NA	FALSE
10.1634/theoncologist.2017-0103	methodology	2	NA	treatment_name_nonipd	pomalidomide + low-dose dexamethasone	Other immunosuppressants	Glucocorticoids	NA	FALSE
10.2147/ceor.s203482	methodology	1	NA	treatment_name_ipd	glasdegib + low-dose cytarabine	Hedgehog pathway inhibitors	Pyrimidine analogues	NA	FALSE
10.2147/ceor.s203482	methodology	1	NA	treatment_name_nonipd	azacitidine	Pyrimidine analogues	NA	NA	FALSE
10.2147/ceor.s203482	methodology	2	NA	treatment_name_ipd	glasdegib + low-dose cytarabine	Hedgehog pathway inhibitors	Pyrimidine analogues	NA	FALSE
10.2147/ceor.s203482	methodology	2	NA	treatment_name_nonipd	decitabine	Pyrimidine analogues	NA	NA	FALSE
10.2147/cmar.s163478	methodology	1	NA	treatment_name_ipd	ribociclib	Cyclin-dependent kinase (CDK) inhibitors	NA	NA	FALSE
10.2147/cmar.s163478	methodology	1	NA	treatment_name_nonipd	palbociclib	Cyclin-dependent kinase (CDK) inhibitors	NA	NA	FALSE
10.2147/cmar.s325043	methodology	1	NA	treatment_name_ipd	ribociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2147/cmar.s325043	methodology	1	NA	treatment_name_nonipd	palbociclib + letrozole	Cyclin-dependent kinase (CDK) inhibitors	Aromatase inhibitors	NA	FALSE
10.2147/cmar.s325043	methodology	2	NA	treatment_name_ipd	placebo + fulvestrant	placebo	Anti-estrogens	NA	FALSE
10.2147/cmar.s325043	methodology	2	NA	treatment_name_nonipd	letrozole	Aromatase inhibitors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	1	NA	treatment_name_ipd	bay 81-8973 (recombinant factor viii)	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	1	NA	treatment_name_nonipd	rahf-pfm	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	2	NA	treatment_name_ipd	bay 81-8973 (recombinant factor viii)	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	2	NA	treatment_name_nonipd	rahf-pfm	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	3	NA	treatment_name_ipd	bay 81-8973 (recombinant factor viii)	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s104074	methodology	3	NA	treatment_name_nonipd	turoctocog alfa	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	1	NA	treatment_name_ipd	bay 94-9027	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	1	NA	treatment_name_nonipd	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	2	NA	treatment_name_ipd	bay 94-9027	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	2	NA	treatment_name_nonipd	bax 855	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	3	NA	treatment_name_ipd	bay 94-9027	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	3	NA	treatment_name_nonipd	rahf-pfm 2004	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	4	NA	treatment_name_ipd	bay 94-9027	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s206806	methodology	4	NA	treatment_name_nonipd	rahf-pfm 2012	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s288283	methodology	1	NA	treatment_name_ipd	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s288283	methodology	1	NA	treatment_name_nonipd	emicizumab every week	Other systemic hemostatics	NA	NA	FALSE
10.2147/jbm.s288283	methodology	2	NA	treatment_name_ipd	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s288283	methodology	2	NA	treatment_name_nonipd	emicizumab every 2 weeks	Other systemic hemostatics	NA	NA	FALSE
10.2147/jbm.s288283	methodology	3	NA	treatment_name_ipd	rfviiifc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s288283	methodology	3	NA	treatment_name_nonipd	emicizumab every 4 weeks	Other systemic hemostatics	NA	NA	FALSE
10.2147/jbm.s312885	methodology	1	NA	treatment_name_ipd	prior prophylaxis rfixfc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s312885	methodology	1	NA	treatment_name_nonipd	prior prophylaxis rix-fp	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s312885	methodology	2	NA	treatment_name_ipd	prior episodic treatment rfixfc	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s312885	methodology	2	NA	treatment_name_nonipd	prior episodic treatment rix-fp	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s321288	methodology	1	NA	treatment_name_ipd	damoctocog alfa pegol (bay 94-9027)	Blood coagulation factors	NA	NA	FALSE
10.2147/jbm.s321288	methodology	1	NA	treatment_name_nonipd	turoctocog alfa pegol (n8-gp)	Blood coagulation factors	NA	NA	FALSE
10.2147/ptt.s326121	methodology	1	NA	treatment_name_ipd	brodalumab	Interleukin inhibitors	NA	NA	FALSE
10.2147/ptt.s326121	methodology	1	NA	treatment_name_nonipd	guselkumab	Interleukin inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	1	NA	treatment_name_ipd	vildagliptin 50 mg twice daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	1	NA	treatment_name_nonipd	sitagliptin 50 mg once daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	2	NA	treatment_name_ipd	vildagliptin 50 mg twice daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	2	NA	treatment_name_nonipd	sitagliptin 50 mg once daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	3	NA	treatment_name_ipd	vildagliptin 50 mg twice daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2165/11592490-000000000-00000	methodology	3	NA	treatment_name_nonipd	sitagliptin 100 mg once daily	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	1	NA	treatment_name_ipd	delayed-release dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	1	NA	treatment_name_nonipd	glatiramer acetate	Other immunostimulants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	2	NA	treatment_name_ipd	delayed-release dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	2	NA	treatment_name_nonipd	glatiramer acetate	Other immunostimulants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	3	NA	treatment_name_ipd	delayed-release dimethyl fumarate	Other immunosuppressants	NA	NA	FALSE
10.2217/cer-2016-0085	methodology	3	NA	treatment_name_nonipd	glatiramer acetate	Other immunostimulants	NA	NA	FALSE
10.2217/cer-2018-0020	methodology	1	NA	treatment_name_ipd	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2018-0020	methodology	1	NA	treatment_name_nonipd	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.2217/cer-2018-0020	methodology	2	NA	treatment_name_ipd	sunitinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2018-0020	methodology	2	NA	treatment_name_nonipd	everolimus	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA	FALSE
10.2217/cer-2018-0141	methodology	1	NA	treatment_name_ipd	secukinumab 150mg	Interleukin inhibitors	NA	NA	FALSE
10.2217/cer-2018-0141	methodology	1	NA	treatment_name_nonipd	infliximab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.2217/cer-2018-0141	methodology	2	NA	treatment_name_ipd	secukinumab 300mg	Interleukin inhibitors	NA	NA	FALSE
10.2217/cer-2018-0141	methodology	2	NA	treatment_name_nonipd	infliximab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.2217/cer-2019-0145	methodology	1	NA	treatment_name_ipd	nivolumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/cer-2019-0145	methodology	1	NA	treatment_name_nonipd	routine clinical practice	supportive or standard of care	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	1	NA	treatment_name_ipd	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	1	NA	treatment_name_nonipd	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	2	NA	treatment_name_ipd	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	2	NA	treatment_name_nonipd	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	3	NA	treatment_name_ipd	ozanimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2019-0169	methodology	3	NA	treatment_name_nonipd	fingolimod	Selective immunosuppressants	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	1	NA	treatment_name_ipd	entrectinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	1	NA	treatment_name_nonipd	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	2	NA	treatment_name_ipd	entrectinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	2	NA	treatment_name_nonipd	pemetrexed + platinum followed by pemetrexed maintenance	Folic acid analogues	Platinum compounds	Folic acid analogues	FALSE
10.2217/cer-2020-0063	methodology	3	NA	treatment_name_ipd	entrectinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/cer-2020-0063	methodology	3	NA	treatment_name_nonipd	pemetrexed/docetaxel	Folic acid analogues	Taxanes	NA	FALSE
10.2217/cer-2020-0069	methodology	1	NA	treatment_name_ipd	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	1	NA	treatment_name_nonipd	blinatumomab	Monoclonal antibodies	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	2	NA	treatment_name_ipd	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	2	NA	treatment_name_nonipd	clofarabine	Purine analogues	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	3	NA	treatment_name_ipd	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	3	NA	treatment_name_nonipd	clofarabine + etoposide plus cyclophosphamide	Purine analogues	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	4	NA	treatment_name_ipd	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	4	NA	treatment_name_nonipd	polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1)	NA	NA	NA	NA
10.2217/cer-2020-0069	methodology	5	NA	treatment_name_ipd	tisagenlecleucel	Other antineoplastic agents	NA	NA	FALSE
10.2217/cer-2020-0069	methodology	5	NA	treatment_name_nonipd	palliative therapy/salvage therapy ± second stem-cell transplantation (salvage-2)	NA	NA	NA	NA
10.2217/cer-2020-0236	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.2217/cer-2020-0236	methodology	1	NA	treatment_name_nonipd	placebo	placebo	NA	NA	FALSE
10.2217/cer-2020-0272	methodology	1	NA	treatment_name_ipd	palbociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer-2020-0272	methodology	1	NA	treatment_name_nonipd	abemaciclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer-2020-0272	methodology	2	NA	treatment_name_ipd	palbociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer-2020-0272	methodology	2	NA	treatment_name_nonipd	ribociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer-2020-0280	methodology	1	NA	treatment_name_ipd	glasdegib + low-dose cytarabine	Hedgehog pathway inhibitors	Pyrimidine analogues	NA	FALSE
10.2217/cer-2020-0280	methodology	1	NA	treatment_name_nonipd	venetoclax + low-dose cytarabine	Other antineoplastic agents	Pyrimidine analogues	NA	FALSE
10.2217/cer-2021-0178	methodology	1	NA	treatment_name_ipd	apomorphine sublingual film	Drugs used in erectile dysfunction	NA	NA	FALSE
10.2217/cer-2021-0178	methodology	1	NA	treatment_name_nonipd	levodopa inhalation powder	Dopa and dopa derivatives	NA	NA	FALSE
10.2217/cer-2021-0216	methodology	1	NA	treatment_name_ipd	risdiplam	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.2217/cer-2021-0216	methodology	1	NA	treatment_name_nonipd	nusinersen	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.2217/cer-2021-0216	methodology	2	NA	treatment_name_ipd	risdiplam	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.2217/cer-2021-0216	methodology	2	NA	treatment_name_nonipd	onasemnogene abeparvovec	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.2217/cer-2021-0216	methodology	3	NA	treatment_name_ipd	risdiplam	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.2217/cer-2021-0216	methodology	3	NA	treatment_name_nonipd	nusinersen	Other drugs for disorders of the musculo-skeletal system	NA	NA	FALSE
10.2217/cer-2021-0221	methodology	1	NA	treatment_name_ipd	palbociclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer-2021-0221	methodology	1	NA	treatment_name_nonipd	abemaciclib + fulvestrant	Cyclin-dependent kinase (CDK) inhibitors	Anti-estrogens	NA	FALSE
10.2217/cer.15.33	methodology	1	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	1	NA	treatment_name_nonipd	telaprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	2	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	2	NA	treatment_name_nonipd	boceprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	3	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	3	NA	treatment_name_nonipd	simeprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	4	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	4	NA	treatment_name_nonipd	sofosbuvir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	5	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	5	NA	treatment_name_nonipd	peginterferon-Î± + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	6	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	6	NA	treatment_name_nonipd	telaprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	7	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	7	NA	treatment_name_nonipd	boceprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	8	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	8	NA	treatment_name_nonipd	simeprevir + peginterferon-Î± + ribavirin	Antivirals for treatment of HCV infections	Interferons	Antivirals for treatment of HCV infections	FALSE
10.2217/cer.15.33	methodology	9	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.33	methodology	9	NA	treatment_name_nonipd	peginterferon-Î± + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.49	methodology	1	NA	treatment_name_ipd	daclatasvir + sofosbuvir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.49	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ribavirin	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.49	methodology	2	NA	treatment_name_ipd	daclatasvir + sofosbuvir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.49	methodology	2	NA	treatment_name_nonipd	peginterferon-alfa + ribavirin	Interferons	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.69	methodology	1	NA	treatment_name_ipd	daclatasvir + asunaprevir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/cer.15.69	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ledipasvir	Antivirals for treatment of HCV infections	Antivirals for treatment of HCV infections	NA	FALSE
10.2217/fon-2020-0823	methodology	1	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	1	NA	treatment_name_nonipd	erlotinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	10	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	10	NA	treatment_name_nonipd	gefitinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	11	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	11	NA	treatment_name_nonipd	dacomitinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	12	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	12	NA	treatment_name_nonipd	dacomitinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	13	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	13	NA	treatment_name_nonipd	panitumumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	14	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	14	NA	treatment_name_nonipd	panitumumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	15	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	15	NA	treatment_name_nonipd	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	16	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	16	NA	treatment_name_nonipd	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	17	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	17	NA	treatment_name_nonipd	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	18	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	18	NA	treatment_name_nonipd	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	19	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	19	NA	treatment_name_nonipd	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	2	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	2	NA	treatment_name_nonipd	erlotinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	20	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	20	NA	treatment_name_nonipd	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	3	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	3	NA	treatment_name_nonipd	platinum-based chemotherapy	Platinum compounds	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	4	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	4	NA	treatment_name_nonipd	platinum-based chemotherapy	Platinum compounds	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	5	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	5	NA	treatment_name_nonipd	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	6	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	6	NA	treatment_name_nonipd	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	7	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	7	NA	treatment_name_nonipd	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	8	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	8	NA	treatment_name_nonipd	cetuximab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	9	NA	treatment_name_ipd	cemiplimab	Monoclonal antibodies	NA	NA	FALSE
10.2217/fon-2020-0823	methodology	9	NA	treatment_name_nonipd	gefitinib	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	1	NA	treatment_name_ipd	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	1	NA	treatment_name_nonipd	entrectinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	2	NA	treatment_name_ipd	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	2	NA	treatment_name_nonipd	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	3	NA	treatment_name_ipd	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/fon-2021-1102	methodology	3	NA	treatment_name_nonipd	crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA	FALSE
10.2217/fon-2021-1509	methodology	1	NA	treatment_name_ipd	avapritinib	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/fon-2021-1509	methodology	1	NA	treatment_name_nonipd	midostaurin	Other protein kinase inhibitors	NA	NA	FALSE
10.2217/imt-2018-0208	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.2217/imt-2018-0208	methodology	1	NA	treatment_name_nonipd	dabrafenib + trametinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.2217/imt-2018-0208	methodology	2	NA	treatment_name_ipd	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.2217/imt-2018-0208	methodology	2	NA	treatment_name_nonipd	vemurafenib + cobimetinib	B-raf serine-threonine kinase (BRAF) inhibitors	Mitogen-activated protein kinase (MEK) inhibitors	NA	FALSE
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	Monoclonal antibodies	Proteasome inhibitors	Other immunosuppressants	FALSE
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone	Proteasome inhibitors	Other immunosuppressants	Glucocorticoids	FALSE
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	Proteasome inhibitors	Other immunosuppressants	Glucocorticoids	FALSE
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone	Proteasome inhibitors	Other immunosuppressants	Glucocorticoids	FALSE
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	Monoclonal antibodies	Proteasome inhibitors	Other immunosuppressants	FALSE
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone	Proteasome inhibitors	Nitrogen mustard analogues	Glucocorticoids	FALSE
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	Proteasome inhibitors	Other immunosuppressants	Glucocorticoids	FALSE
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone	Proteasome inhibitors	Nitrogen mustard analogues	Glucocorticoids	FALSE
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	Monoclonal antibodies	Proteasome inhibitors	Other immunosuppressants	FALSE
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_nonipd	bortezomib + dexamethasone	Proteasome inhibitors	Glucocorticoids	NA	FALSE
10.2217/imt-2020-0266	methodology	6	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	Proteasome inhibitors	Other immunosuppressants	Glucocorticoids	FALSE
10.2217/imt-2020-0266	methodology	6	NA	treatment_name_nonipd	bortezomib + dexamethasone	Proteasome inhibitors	Glucocorticoids	NA	FALSE
10.2217/imt-2021-0273	methodology	1	NA	treatment_name_ipd	pembrolizumab	Monoclonal antibodies	NA	NA	FALSE
10.2217/imt-2021-0273	methodology	1	NA	treatment_name_nonipd	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.3111/13696998.2013.768530	methodology	1	NA	treatment_name_ipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.3111/13696998.2013.768530	methodology	1	NA	treatment_name_nonipd	etanercept	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.3111/13696998.2013.768530	methodology	2	NA	treatment_name_ipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.3111/13696998.2013.768530	methodology	2	NA	treatment_name_nonipd	infliximab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.3390/biom11060780	methodology	1	NA	treatment_name_ipd	gemcitabine + nab-paclitaxel	Pyrimidine analogues	Taxanes	NA	FALSE
10.3390/biom11060780	methodology	1	NA	treatment_name_nonipd	folfirinox	ANTINEOPLASTIC AGENTS	NA	NA	FALSE
10.3390/cancers12123648	methodology	1	NA	treatment_name_ipd	pembrolizumab + chemotherapy	Monoclonal antibodies	ANTINEOPLASTIC AGENTS	NA	FALSE
10.3390/cancers12123648	methodology	1	NA	treatment_name_nonipd	nivolumab + ipilimumab	Monoclonal antibodies	Monoclonal antibodies	NA	FALSE
10.3390/cancers13102406	methodology	1	NA	treatment_name_ipd	padua surgical aggressive downstaging	ANTINEOPLASTIC AGENTS	NA	NA	FALSE
10.3390/cancers13102406	methodology	1	NA	treatment_name_nonipd	xxl protocol downstaging	ANTINEOPLASTIC AGENTS	NA	NA	FALSE
10.36469/jheor.2021.19008	methodology	1	NA	treatment_name_ipd	remestemcel-l-rknd	IMMUNOSUPPRESSANTS	NA	NA	FALSE
10.36469/jheor.2021.19008	methodology	1	NA	treatment_name_nonipd	ruxolitinib	Janus-associated kinase (JAK) inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2018.18162	methodology	1	NA	treatment_name_ipd	secukinumab	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2018.18162	methodology	1	NA	treatment_name_nonipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2018.18162	methodology	2	NA	treatment_name_ipd	secukinumab	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2018.18162	methodology	2	NA	treatment_name_nonipd	adalimumab	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	1	NA	treatment_name_ipd	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	1	NA	treatment_name_nonipd	etanercept	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	2	NA	treatment_name_ipd	secukinumab 150 mg	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	2	NA	treatment_name_nonipd	etanercept	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	3	NA	treatment_name_ipd	secukinumab 300mg	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	3	NA	treatment_name_nonipd	etanercept	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	4	NA	treatment_name_ipd	secukinumab 300mg	Interleukin inhibitors	NA	NA	FALSE
10.5152/eurjrheum.2019.19057	methodology	4	NA	treatment_name_nonipd	etanercept	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA	FALSE
